Coronary Heart Disease

Paclitaxel was selected as the drug to coat the stent because it is known to prevent the uncontrolled cell growth that contributes to the narrowing of artery, by interfering with the ability of cells to divide and multiply. Because of these properties, it has been used as a drug for the treatment of various types of cancer. Cancer patients are given paclitaxel as a solution into the vein. For this study, paclitaxel will be administered locally to the wall of coronary artery as a coating on the stent. Cancer patients receive a dose of paclitaxel approximately 1100 - 1400 times greater than the dose used in the coating of the stent. It is highly unlikely that levels of paclitaxel in the blood would be measurable or have effects anywhere beyond the heart.

TAXUS Element Stent or TAXUS Express Stent

A Prospective Evaluation in a Randomized Trial of TAXUS in the Treatment of De Novo Coronary Artey Lesions

A Prospective Evaluation in a Randomized Trial of the Safety and Efficacy of the Use of the TAXUS® ElementTM Paclitaxel-Eluting Coronary Stent System for the Treatment of De Novo Coronary Artery Lesions

National University Hospital, Singapore

Boston Scientific Corporation

749 patients will be assigned into nab-Paclitaxel group.

749 patients will be assigned into paclitaxel group

Breast Cancer

Nab-P (Abraxis BioScience, LLC., Mclrose Park, IL, USA; drug license No. H20091059), 125 mg/m2, intravenous drip for 30 minutes once, on days 1 and 8, 21 days as a session for a total of 6 sessions; at the same time, carboplatin (Qilu Pharmaceutical Co., Ltd., Jinan, Shandong Province, China; drug license No. Guoji Zhunzi H20020181), AUC=2 mg•min/mL, intravenous drip for 120 minutes once, on days 1 and 8, 21 days as a session for a total of 6 sessions.

nab-Paclitaxel+carboplatin

Paclitaxel (Yangtze River Pharmaceutical Co., Ltd., Taizhou, Jiangsu Province, China; drug license No. Guoyao Zhunzi H20053001), 125 mg/m2, intravenous drip for 30 minutes once, on days 1 and 8, 21 days as a session for a total of 6 sessions; at the same time, carboplatin, AUC=2 mg•min/mL, intravenous infusion for 120 minutes once, on days 1 and 8, 21 days as a session for a total of 6 sessions.

Paclitaxel+carboplatin

Shengjing Hospital of China Medical University

Treatment of Triple-negative Breast Cancer With Albumin-bound Paclitaxel as Neoadjuvant Therapy: a Prospective RCT

Treatment of Triple-negative Breast Cancer With Albumin-bound Paclitaxel as Neoadjuvant Therapy: a Prospective Randomized Controlled Clinical Trial

Pathologic complete remission refers to no invasive tumor cell remnants in the pathological examination of the primary mammary gland and axillary lymph nodes surgically removed. The PCR indicates the proportion of the patients with pathological complete remission to the total number of patients.

The CD44/CD24 expression in the breast tissues will be detected by immunohistochemistry before treatment and at 9 and 18 weeks of treatment, to determine the proportion of tumor stem cells in the lesion.

PFS refers to the time from random enrollment to disease progression or death for any reason indicated by imaging findings. PFS will be recorded within 5 years of follow-up.

OS refers to the time from enrollment to death

Any untoward medical occurrence in a patient and which does not necessarily have a causal relationship with this treatment.

Caigang Liu

Principal Investigator

Shengjing Hospital

Esophageal Squamous Cell Carcinoma

Apatinib

Recurrence

Metastasis

apatinib

Shanghai Chest Hospital

Apatinib in the Treatment of Recurrence or Metastasis of Esophageal Cancer

Prospective,Single-arm,and Exploratory Phase II Clinical Study for the Efficacy of Apatinib in the Treatment of Recurrence or Metastasis of Esophageal Squamous Cell Carcinoma After Radical Resection

Zhigang Li

Director, Head of esophageal surgery

Drugs screened by the Alphacait screening system will be administered in accordance with the protocol of the drug specification or the CPSC guidelines until the patient progresses, intolerant, the patient withdrawn or the investigator determines that the medication must be discontinued.

Metastatic Cancer

Drugs screened by the Alphacait screening system will be administered in accordance with the protocol of the drug specification or the CPSC guidelines.

Non Chemotherapy

Chemotherapy and target therapy

Chinese herb medicine

Sir Run Run Shaw Hospital, affiliated with Zhejiang University School of medicine

Clinical Studies by Using Alphacait to Screen Drugs for Advanced Solid Tumor

Clinical Studies by Using Alphacait to Screen Drug Combinations for Advanced Solid Tumor

Progression-free survival (PFS) is defined as the time from assignment in the trial to disease progression or death from any cause.

Defined as the time from assignment to death from any cause.

Overall response rate (ORR) is defined as the proportion of patients who have a partial or complete response to therapy

Overall response rate (ORR) is defined as the proportion of patients who have a partial or complete response or stable disease to therapy

Drug-related adverse reactions must be recorded, mainly in the following：myelosuppression including neutropenia, anemia and thrombocytopenia;Cardiac toxicity; muscle fatigue, pain, imbalance; Oral ulcers: the patient's gums, cheeks, throat and tongue are prone to ulcers;nausea, vomiting, constipation or diarrhea;hair loss;skin discomfort;hormonal fluctuations, sexual dysfunction, infertility; damage of the kidney;anxiety and depression.

Expectations of exploratory markers for this study include the status of exploratory biomarkers associated with immunohistochemistry (IHC) or quantitative reverse transcription polymerase chain reaction (qRT-PCR), a new generation sequencing method (NGS), Nanostring technique and / or other methods to evaluate archived and/or newly acquired tumor tissue, as well as its association with disease status and/or (Including but not limited to somatic mutations and other exploratory markers) according to qRT-PCR and NGS techniques, and to evaluate the relationship between the therapeutic response, the status of the biomarker during exploratory treatment and during treatment, and the evaluation of plasma, serum or whole blood samples (including but not limited to somatic mutations and other exploratory markers) The association of the above markers with disease status and / or therapeutic response.

Through publication after study completion

Haining Health-Coming Biotech Co., Ltd.

Alphacait, LLC

This single center, open-label, single arm, non-randomized study is designed to evaluate safety, progression-free survival(PFS),overall survival (OS), objective response rate (OPR), and disease control rate (DCR) of chemotherapy or target therapy or chinese medicine based on the Alphacait screening system in subjects with advanced malignant tumor.

Paclitaxel eluting covered metal stent group

Bile Duct Obstruction

Paclitaxel eluting covered metal stent and control covered metal stent are inserted with standard ERCP technique

Paclitaxel eluting covered metal stent and control covered metal stent

Asan Medical Center

Paclitaxel Eluting Covered Metallic Stent for Unresectable Malignant Bile Duct Obstruction

Randomized Trial of Conventional Covered Self Expandable Metallic Stent Versus Paclitaxel Eluting Covered Self Expandable Metallic Stent in Unresectable Malignant Bile Duct Obstruction

taxus/neoplasms

A Prospective Evaluation in a Randomized Trial of TAXUS in the Treatment of De Novo Coronary Artey Lesions

Treatment of Triple-negative Breast Cancer With Albumin-bound Paclitaxel as Neoadjuvant Therapy: a Prospective RCT

Apatinib in the Treatment of Recurrence or Metastasis of Esophageal Cancer

Clinical Studies by Using Alphacait to Screen Drugs for Advanced Solid Tumor

Paclitaxel Eluting Covered Metallic Stent for Unresectable Malignant Bile Duct Obstruction

科学支持的最完整的草药数据库